Artificial intelligence and machine learning are transforming acute respiratory distress syndrome (ARDS) management, enabling earlier detection, precision risk stratification, and tailored therapies. Emerging AI techniques promise to improve outcomes, but real-world clinical validation and integration remain critical challenges.